ARCT-154

ARCT-154 is an RNA vaccine that is currently under development by Arcturus Therapeutics for the prevention of COVID-19. The vaccine is based on the company's proprietary LUNAR platform, which uses self-replicating RNA (srRNA) and is encapsulated in lipid nanoparticles.

Development

ARCT-154 is a next-generation vaccine candidate that is being developed to address the emerging SARS-CoV-2 variants. The vaccine is designed to target the Spike protein of the SARS-CoV-2 virus, including the D614G mutation, which is common in several variants of the virus.

In preclinical studies, ARCT-154 demonstrated a strong neutralizing antibody response against the original SARS-CoV-2 virus and several of its variants. The vaccine is currently in Phase 1/2 clinical trials.

Clinical Trials

The Phase 1/2 clinical trial for ARCT-154 is a randomized, double-blind, placebo-controlled study that aims to evaluate the safety, tolerability, and immunogenicity of the vaccine in healthy adults. The trial is being conducted in the United States and Singapore.

Mechanism of Action

ARCT-154 uses Arcturus Therapeutics' proprietary LUNAR platform to deliver self-replicating RNA (srRNA) into cells. The srRNA is designed to mimic the virus's genetic material, prompting the cells to produce the virus's spike protein. This triggers an immune response, which includes the production of antibodies that can neutralize the virus.

See Also

• COVID-19 vaccine
• Arcturus Therapeutics
• RNA vaccine
• LUNAR platform
• SARS-CoV-2 variants